Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent

Breast Cancer Research and Treatment

Volumn 70, Issue 3, 2001, Pages 197-204

  Tuck, Alan B ^a,b,c   Hota, Charulata ^a,b,c   Chambers, Ann F ^a,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Breast cancer; Cell invasion; Mammary epithelial cells; Osteopontin (OPN); Urokinase (uPA)

Indexed keywords

4 AMINOBENZAMIDINE; AMILORIDE; APROTININ; ENZYME ANTIBODY; IMMUNOGLOBULIN G; MATRIGEL; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CELL INVASION; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BLOTTING, NORTHERN; BREAST; CELL ADHESION; CELL MOVEMENT; COLLAGEN; DRUG COMBINATIONS; EPITHELIAL CELLS; FEMALE; HUMANS; LAMININ; OSTEOPONTIN; PROTEOGLYCANS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; RNA, NEOPLASM; SIALOGLYCOPROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035678921     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013095329825     Document Type: Article

References (38)

1. Osteopontin expression in a group of lymph node negative breast cancer patients
2. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival
3. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells
4. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade
5. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
6. ECM and cell surface proteolysis: Regulating cellular ecology
7. The urokinase-type plasminogen activator system in cancer metastasis: A review
8. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration
9. Urokinase receptor interacts with αvβ5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer
10. Tumor progression in four mammary epithelial cell lines derived from the same patient
11. Ras transfection and expression does not induce progression from tumorigenicity to metastatic ability in mouse LTA cells
12. Different patterns of gene expression in ras-resistant and ras-sensitive cells
13. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN)
14. The human urokinase-plasminogen activator gene and its promoter
15. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
16. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase, on urokinase expression and in vitro invasion
17. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions
18. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion
19. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases - A comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases
20. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin
21. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met)
22. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration
23. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype
24. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model
25. Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line
26. A biochemical characterization of the binding of osteopontin to integrins alpha v beta1 and alpha v beta5
27. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta3 in smooth muscle cell migration to osteopontin in vitro
28. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9 beta1 integrin
29. Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis
30. Osteopontin is a ligand for the alpha4 beta1 integrin
31. Receptor-ligand interaction between CD44 and osteopontin (Eta-1)
32. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells
33. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis
34. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network
35. Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells
36. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor
37. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
38. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network